Q4 FY26 Earnings Results
Q4 FY26 earnings, Jan–Mar 2026: 5,781 Indian listed companies have reported; median profit growth is +5.8% on last year, and 220 of 401 companies with analyst estimates beat them. Quarter ended 31 Mar 2026.
Reported
5,781
companies
Profit breadth
52% / 45%
grew / declined · 4,024 comparable
Median sales YoY
+11.8%
across all reporters
Median profit YoY
+5.8%
across all reporters
Beat / missed
220 / 145
of 401 covered
Strongest / weakest
Energy +44.0%
Commodities −59.7%
median profit growth, 10+ reporters
Clear filters 201–270 of 270
| Company | Revenue (₹ Cr) | Profit (₹ Cr) | Per share | 8Q profit | |||||
|---|---|---|---|---|---|---|---|---|---|
| Symbol | Sector | Reported | YoY | QoQ | Reported | YoY | EPS | vs consensus | Trend |
 ACCRETIONNUTRAVEDALTD | Healthcare | 20 | up+80.1% | n/a | 3 | up+56.4% | 3.72 | No estimate | |
 AMKAYPRODUCTSLTD | Healthcare | 19 | down−7.4% | n/a | 0 | down−77.5% | 0.39 | No estimate | |
 PREVESTLTD Prevest Denpro Ltd | Healthcare | 19 | up+1.9% | up+2.9% | 6 | up+15.4% | 5.05 | No estimate | |
 VINEETLAB Vineet Laboratories Ltd | Healthcare | 19 | up+34.2% | up+20.7% | 1 | n/a | 0.38 | No estimate | |
 Goldline Pharmaceutical Ltd | Healthcare | 17 | n/a | n/a | 3 | n/a | 4.00 | No estimate | |
 Cian Healthcare Ltd | Healthcare | 17 | up+41.7% | n/a | −18 | n/a | −7.19 | No estimate | |
 SANDUPHARMACEUTICALSLTD | Healthcare | 17 | up+19.8% | down−10.2% | 0 | down−87.9% | 0.04 | No estimate | |
 VEERHEALTHCARELTD | Healthcare | 17 | up+198.2% | up+130.9% | 0 | n/a | −0.18 | No estimate | |
 TYCHEINDUSTRIESLTD | Healthcare | 16 | up+31.0% | up+53.1% | 1 | up+22.3% | 1.12 | No estimate | |
 FABINOLTD Fabino Enterprises Ltd | Healthcare | 14 | up+3.1% | n/a | 0 | down−1,333.3% | −1.76 | No estimate | |
 VIVOBIOT Vivo Bio Tech Ltd | Healthcare | 14 | up+15.5% | up+5.1% | −5 | down−586.8% | −2.33 | No estimate | |
 MOMSBELIEF Rays of Belief Ltd | Healthcare | 13 | n/a | n/a | 1 | n/a | 0.53 | No estimate | |
 SANJIVANIPARANTERALLTD | Healthcare | 13 | down−27.3% | down−40.1% | 1 | down−74.9% | 0.45 | No estimate | |
 APRAMEYA Aprameya Engineering Ltd | Healthcare | 13 | down−90.0% | n/a | −2 | down−109.6% | −0.90 | No estimate | |
 CENTENIALSURGICALSUTURELTD | Healthcare | 13 | down−5.5% | down−15.3% | −2 | n/a | −6.33 | No estimate | |
 VIVIMEDLAB Vivimed Labs Ltd | Healthcare | 12 | down−53.8% | down−25.0% | −147 | n/a | −17.74 | No estimate | |
 VASUNDHARARASAYANSLTD | Healthcare | 12 | up+53.2% | up+59.6% | 2 | up+451.1% | 7.80 | No estimate | |
 Satiate Agri Ltd | Healthcare | 12 | n/a | n/a | −1 | n/a | −3.86 | No estimate | |
 GUJARATTERCELABORATORIESLTD | Healthcare | 11 | down−7.5% | down−7.2% | 0 | n/a | 0.13 | No estimate | |
 ZENOTECHLABORATORIESLTD | Healthcare | 10 | down−18.5% | down−23.1% | −3 | down−356.1% | −0.52 | No estimate | |
 AUROLABORATORIESLTD | Healthcare | 10 | up+32.8% | up+4.7% | 1 | up+148.7% | 1.56 | No estimate | |
 PHAARMASIALTD | Healthcare | 8 | up+42.4% | down−51.8% | −1 | n/a | −1.03 | No estimate | |
 BIOFILCHEM Biofil Chemicals & Pharmaceuticals Ltd | Healthcare | 8 | down−9.3% | up+780.2% | 0 | up+5.0% | 0.13 | No estimate | |
 PHARMAIDSPHARMACEUTICALSLTD | Healthcare | 7 | up+50.5% | up+32.2% | −1 | n/a | −0.51 | No estimate | |
 KREBSBIO Krebs Biochemicals & Industries Ltd | Healthcare | 7 | up+11.6% | down−6.3% | −2 | n/a | −1.09 | No estimate | |
 GKB GKB Ophthalmics Ltd | Healthcare | 6 | down−24.1% | up+46.8% | −2 | n/a | −3.73 | No estimate | |
 VIVANZABIOSCIENCESLTD | Healthcare | 6 | up+1,225.0% | down−85.9% | 0 | n/a | −0.11 | No estimate | |
 SHUKRAPHAR Shukra Pharmaceuticals Ltd | Healthcare | 6 | down−53.8% | down−84.6% | −2 | down−140.0% | −0.04 | No estimate | |
 KMSMEDISURGILTD | Healthcare | 6 | down−8.7% | n/a | 0 | down−97.2% | 0.03 | No estimate | |
 BERYLDRUGSLTD | Healthcare | 5 | up+4.8% | up+42.1% | 1 | up+273.3% | 1.10 | No estimate | |
 SHREEPACETRONIXLTD | Healthcare | 5 | up+25.5% | up+24.0% | 1 | up+146.7% | 2.96 | No estimate | |
 MEDIORG Medicamen Organics Ltd | Healthcare | 5 | down−77.8% | n/a | −6 | down−338.6% | −4.98 | No estimate | |
 Span Divergent Ltd | Healthcare | 5 | up+745.5% | up+20.5% | −1 | n/a | −1.32 | No estimate | |
 ACHYUTHEALTHCARELTD | Healthcare | 4 | up+377.2% | up+179.6% | 0 | down−50.0% | 0.00 | No estimate | |
 A D S Diagnostic Ltd | Healthcare | 4 | up+19.9% | down−26.0% | 0 | up+71.4% | 0.55 | No estimate | |
| VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals Ltd | Healthcare | 4 | up+1,093.9% | up+154.2% | 0 | down−85.9% | 0.09 | No estimate | |
 DECIPHERLABSLTD | Healthcare | 4 | up+2.9% | up+12.1% | 0 | n/a | −0.36 | No estimate | |
 DESHRAKSHAKAUSHDHALAYALTD | Healthcare | 3 | down−21.4% | up+146.4% | 0 | down−16.7% | 0.53 | No estimate | |
 UNJHAFORMULATIONSLTD | Healthcare | 3 | up+36.5% | down−25.0% | −1 | n/a | −1.65 | No estimate | |
 PARMAXPHARMALTD | Healthcare | 3 | down−31.5% | down−23.6% | −1 | n/a | −1.55 | No estimate | |
 ISHITADRUGSINDUSLTD Ishita Drugs & Industries Ltd | Healthcare | 3 | down−32.9% | down−2.5% | 0 | down−37.9% | 0.60 | No estimate | |
| Sangam Health Care Products Ltd | Healthcare | 3 | up+3.1% | down−2.2% | 0 | down−247.4% | −0.19 | No estimate | |
 ZENITHHEALTHCARELTD | Healthcare | 3 | down−23.6% | up+5.6% | 0 | down−409.1% | −0.06 | No estimate | |
 SHREEGANESHBIOTECHINDIALTD | Healthcare | 2 | down−29.6% | up+202.9% | 0 | n/a | 0.00 | No estimate | |
 DIPNAPHARMACHEMLTD | Healthcare | 2 | down−87.1% | down−96.2% | 0 | down−64.0% | 0.07 | No estimate | |
 SUVEN Suven Life Sciences Ltd | Healthcare | 2 | up+100.0% | down−33.3% | −46 | n/a | −1.73 | No estimate | |
 BRAWNPHARMACEUTICALSLTD Brawn Biotech Ltd | Healthcare | 2 | down−12.4% | down−54.1% | 1 | n/a | 1.93 | No estimate | |
 COLINZLABORATORIESLTD | Healthcare | 2 | up+20.7% | up+22.4% | 0 | up+13.3% | 0.67 | No estimate | |
 AMBALALSA Ambalal Sarabhai Enterprises Ltd | Healthcare | 2 | down−12.1% | n/a | 3 | n/a | 0.35 | No estimate | |
 VANTABIOSCIENCELTD | Healthcare | 2 | up+357.6% | n/a | 2 | n/a | 2.71 | No estimate | |
 GANGAPHARMACEUTICALSLTD | Healthcare | 1 | up+9.8% | n/a | 0 | up+33.3% | 0.14 | No estimate | |
 NECLIFE Nectar Lifescience Ltd | Healthcare | 1 | n/a | n/a | −68 | n/a | −3.50 | No estimate | |
| REKVINALABORATORIESLTD Rekvina Labs Ltd | Healthcare | 1 | n/a | up+105.7% | 0 | n/a | −0.05 | No estimate | |
 MEDICAPQ Medi Caps Ltd | Healthcare | 1 | down−40.4% | down−31.2% | 0 | down−143.7% | −0.25 | No estimate | |
 ORTINGLOBE Ortin Global Ltd | Healthcare | 0 | up+233.3% | up+2,900.0% | 0 | n/a | −0.01 | No estimate | |
 TRANSPACTENTERPRISESLTD | Healthcare | 0 | up+12.5% | n/a | 0 | down−20.0% | 1.03 | No estimate | |
 SHYAMAINFOLTD Shyama Computronics and Services Ltd | Healthcare | 0 | down−14.3% | down−14.3% | 0 | down−77.8% | 0.02 | No estimate | |
| GENESISIBRCINDIALTD CCME Global Ltd | Healthcare | 0 | n/a | n/a | −1 | n/a | −0.11 | No estimate | |
 GENOMICVALLEYBIOTECHLTD | Healthcare | 0 | down−84.6% | down−20.0% | 0 | n/a | −0.03 | No estimate | |
 TRANSCHEMLTD | Healthcare | 0 | down−100.0% | n/a | 2 | up+186.3% | 1.71 | No estimate | |
 CHEMOPHARMALABORATORIESLTD Starsource Multitrade Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.47 | No estimate | |
 TRIOCHEMPRODUCTSLTD | Healthcare | 0 | n/a | n/a | 8 | n/a | 340.00 | No estimate | |
 BACILPHARMALTD | Healthcare | 0 | n/a | n/a | 1 | up+3,000.0% | 0.43 | No estimate | |
 KAMRONLABORATORIESLTD Adline Chem Lab Ltd | Healthcare | 0 | n/a | n/a | 0 | down−142.9% | −0.15 | No estimate | |
 WELCUREDRUGSPHARMACEUTICALSLTD Welcure Drugs & Pharmaceuticals Ltd | Healthcare | 0 | down−100.0% | n/a | −50 | down−1,766.7% | −0.40 | No estimate | |
 VISTAPHARMACEUTICALSLTD | Healthcare | 0 | down−100.0% | down−100.0% | −6 | n/a | −0.95 | No estimate | |
| RAYMEDLABSLTD Cresanto Global Limited | Healthcare | 0 | n/a | n/a | 0 | down−442.9% | −0.56 | No estimate | |
| MPS Pharmaa Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.19 | No estimate | |
 Transchem Ltd | Healthcare | 0 | down−100.0% | n/a | 2 | up+186.3% | 1.71 | No estimate | |
 LASA Lasa Supergenerics Ltd | Healthcare | 0 | down−100.3% | down−105.9% | −4 | n/a | −0.83 | No estimate | |
About Q4 FY26 earnings data
When are Q4 FY26 results announced?
Q4 FY26 covers the Jan–Mar 2026 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q4 FY26 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No, and the denominator matters. An analyst consensus existed for 401 of the 5,781 companies that reported Q4 FY26 — 6.9%. Beat, missed and in-line describe only those. Every other company is marked "no estimate" rather than being counted as in line, because nobody forecast it. Revenue and profit growth, by contrast, cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q4 FY26?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.
Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.